October 2, 2012   

OVA1 & Managing Adnexal Masses                                               

Keynote Speaker for this Event:

                                         Michael D. Randell, MD, FACOG    
                                         Department of Obstetrics and Gynecology
                                         Northside Hospital
                                         Atlanta, Georgia

OVA1 & Managing Adnexal Masses

This webinar will provide a review of current adnexal mass management practices, including:

• Improvements in patient care with the addition of recently cleared blood tests
• Criteria necessary for utility of blood tests when used to identify potential ovarian malignancy
• Potential for improved outcomes with appropriate referrals when necessary

Dr. Randell will discuss 3 case studies demonstrating benefit of including a blood test as part of preoperative assessment.

At the conclusion of the presentation you will have a clear understanding in the role multi-marker blood tests play in the management of patients with an adnexal mass.

OVA1® is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using a unique multi-biomarker approach.

In a published clinical trial, OVA1 achieved 99% sensitivity in detecting epithelial ovarian cancers (EOC). This included 96% sensitivity for stage I EOC, the earliest and most curable EOC stage, compared with 57% for the conventional biomarker CA125.1 In addition, OVA1 found 70% of malignancies missed by non-specialist pre-surgical assessment,(1) and it increased detection of malignancy over ACOG guidelines from 77% to 94%.2 As the first protein-based, In Vitro Diagnostic Multi-Variate Index Assay (IVDMIA) cleared by the FDA, OVA1 also represents a new class of software-based diagnostics. For more information visit http://www.ova-1.com/

References:
1) Ueland, FR, et al. Obstet Gynecol 2011:VOL 117, NO. 6, June 2011
2) Miller R, et al. Obstet Gynecol 2011:VOL 117, NO. 6, June 2011

Gynecologists, obstetricians, family practitioners and internists

Michael D. Randell, M.D., F.A.C.O.G. is a board certified Obstetrician and Gynecologist. Dr. Randell earned his Bachelor of Science degree from Emory University in Atlanta and completed his Medical degree with Research Distinction from the University of Miami School of Medicine in Miami, Florida. He received his training in Obstetrics and Gynecology at the University of Miami/Jackson Memorial Medical Center--one of the largest hospitals for obstetrics in the United States.

Dr. Randell is included in the list of "Top Doctors" in Atlanta. This distinction was awarded to Dr. Randell by Atlanta doctors, nurses and administrators who were surveyed and said that Dr. Randell was the OB/GYN practice where they would send a member of their family or friend.

Dr. Randell enjoys delivering babies and providing routine comprehensive gynecological care to patients from adolescence through menopause. His special clinical interests are in medical complications of pregnancy, management of abnormal Pap smears, vaginal and urogynecological surgery, and operative laparoscopy.

His research interests in managing cancer during pregnancy, the treatment of atypical Pap smears, and the effects of barometric pressure changes on the initiation of labor, have led to award winning presentations at scientific and medical meetings. In addition to his research presentations, Dr. Randell is regularly invited to speak at conferences throughout the country on the management of abnormal Pap smears, menopause, and oral contraception.

Dr. Randell serves on advisory panels of several pharmaceutical companies and is frequently interviewed by the news media on issues related to women's health care. Dr. Randell has appeared on CNN, Fox News, America's Health Network, and on all local Atlanta television stations. He also has been featured in Glamour Magazine, Shape Magazine, the Associated Press, and in the Atlanta Journal Constitution.

Dr. Randell is a Diplomate of the American Board of Obsterics and Gynecology and the National Board of Medical Examiners. He also is a Fellow of the American College of Obstetricians and Gynecologists and is an active member of the American Medical Association, American Association of Gynecologic Laparoscopists, and the North American Menopause Society.

Vermillion, Inc., is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has ongoing programs in oncology/hematology, cardiology and women’s health. Our initial focus is ovarian cancer with OVA1® being the first FDA-cleared blood test for the preoperative assessment of ovarian tumors.